Is Lexapro (escitalopram) addictive?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Lexapro Addictive?

No, Lexapro (escitalopram) is not addictive. While it may cause withdrawal symptoms upon discontinuation, it does not produce drug-seeking behavior or addiction patterns typical of substances with abuse potential.

Understanding Lexapro and Addiction

Lexapro belongs to the class of selective serotonin reuptake inhibitors (SSRIs) that are used to treat depression and anxiety disorders. According to high-quality evidence:

  • Antidepressants, including SSRIs like Lexapro, are not associated with a risk of dependence or addiction 1
  • The FDA label for escitalopram specifically states that animal studies suggest low abuse liability, and premarketing clinical experience did not reveal any drug-seeking behavior 2

Withdrawal vs. Addiction

It's important to distinguish between withdrawal symptoms and addiction:

Withdrawal Symptoms

  • Abrupt discontinuation of Lexapro may lead to withdrawal symptoms including:

    • Anxiety
    • Dizziness
    • Sensory disturbances (e.g., electric shock sensations)
    • Sleep disturbances
    • Irritability
    • Headache
  • These symptoms typically begin 2-10 days after stopping the medication and usually resolve within a few weeks 1

  • Some patients may experience more protracted withdrawal symptoms

Why This Is Not Addiction

  • Addiction involves:

    • Compulsive drug-seeking behavior
    • Use despite harmful consequences
    • Inability to control use
    • Development of tolerance requiring dose escalation
    • Drug craving
  • Lexapro does not produce these addiction patterns:

    • Patients don't typically seek higher doses than prescribed
    • There is no evidence of drug-seeking behavior 2
    • There is no black market for Lexapro
    • Patients don't typically misuse the medication for euphoric effects

Proper Discontinuation

To minimize withdrawal symptoms when stopping Lexapro:

  • Gradual tapering is recommended over 10-14 days or longer 1
  • Tapering schedules should be individualized based on:
    • Duration of treatment
    • Dose
    • Individual patient factors
  • Monitoring for withdrawal symptoms during the tapering process

Comparison with Truly Addictive Substances

Unlike Lexapro, certain other psychiatric medications do carry addiction risks:

  • Benzodiazepines (e.g., lorazepam, diazepam) can lead to tolerance, addiction, and physical dependence 1, 3
  • Z-drugs (e.g., zolpidem, zopiclone) were initially believed to have low risk of dependence but are now known to carry addiction potential 1
  • Opioids have high addiction potential and are associated with drug-seeking behavior 1

Special Considerations

  • Patients with a history of substance abuse should be monitored more closely when prescribed any medication, including Lexapro 2
  • Regular assessment of continued need for medication is appropriate
  • Patients should be educated about potential withdrawal symptoms to prevent misinterpreting them as relapse of depression or anxiety

Common Misconceptions

A common misconception is confusing withdrawal symptoms with addiction. While withdrawal symptoms indicate physical dependence (a normal physiological adaptation), they do not indicate addiction, which involves psychological craving and compulsive use.

In conclusion, while patients may experience withdrawal symptoms when discontinuing Lexapro, the medication is not considered addictive based on its pharmacological properties and clinical evidence.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Anxiolytic drugs: dependence, addiction and abuse.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1994

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.